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Abstract
Background: The association between intake of non-phenacetin-containing analgesics and the occurrence of
chronic renal failure is still controversially discussed. A new epidemiologic study was planned and conducted in
Germany and Austria.
Methods/design:  The objective of the international, multicenter case-control study was to evaluate the
association between end-stage renal disease (ESRD) and use of non-phenacetin-containing analgesics with
particular emphasis on combined formulations. A targeted sample of 1000 new (incident) dialysis patients, aged
less than 50 years, was planned to recruit between January 1, 2001 and December 31, 2004. The age limit was
chosen to avoid contamination of the study population with phenacetin-containing analgesics to the extent
possible. Four control subjects per ESRD case, matched by age, sex, and region were selected from the population
living in the region the case came from.
Lifetime exposure to analgesics and potential renal risk factors were recorded in a single face-to-face interview.
A set of aids was introduced to reinforce the memory of study participants.
A standardized, pre-tested interview questionnaire (participants), a medical documentation sheet (physicians in
dialysis centres), a logbook for all activities (dialysis centres) were used to collect the necessary data.
Quality management consisted of the standardized procedures, (re-) training and supervision of interviewers,
regular checks of all incoming data for completeness and plausibility.
The study is scientifically independent and governed by a international Scientific Advisory Committee that bridged
the gap between the sponsoring companies and the investigators. Also other advisory groups assisted the
managing committee of the study. All relevant German and Austrian nephrological associations supported the
study, and the study design was carefully reviewed and approved by the Kidney Foundation of Germany.
Discussion: The study is expected to answer the main research question by end 2005. There is however a high
potential for various biases that we tried to address with adequate measure. One limitation however cannot be
overcome: The methodologically needed age-limitation of the study will make it not easy to generalize the results
to age groups over 50 years. It might be suggested to repeat the study for persons over 50 years in 10 years when
contamination with phenacetin use early in life is likely to be outgrown.
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Background
It was long time ago that Dubach et al. published their
paper on phenacetin nephropathy [1]. At that time, phen-
acetin-containing analgesics were freely available in bulk
to all workers in the Swiss watch industry [1], and sachets
of phenacetin-containing analgesic powders were even
given as a tip for small services to apprentices in the Husk-
varna factory in Sweden [2]. Several epidemiological stud-
ies were undertaken to clarify the association between
phenacetin overuse and development of end stage renal
disease (ESRD)1 (see [3,4] for review). As a result, phen-
acetin was banned at different times in almost all states of
the world. However, although "phenacetin nephropathy"
– thought to develop only after decades of chronic phen-
acetin overuse – could not be expected to disappear soon,
nephrologists suspected that non-phenacetin analgesic
combinations, especially those containing paracetamol
and aspirin (plus caffeine) might cause ESRD as well and
introduced the hypothetical term "analgesic nephropa-
thy". Since empirical data were scarce, this hypothesis
engendered some controversy. Safety concerns led the reg-
ulatory authorities of Germany, Austria and Switzerland
to initiate a scientific re-evaluation. A peer review commit-
tee of scientists was jointly selected by the regulatory
authorities and the pharmaceutical industry and was
asked to critically review data on the relationship between
non-phenacetin combined analgesics and nephropathy.
The committee's two main conclusions were that (1) there is
insufficient evidence to associate non-phenacetin combined
analgesics with nephropathy and that (2) new studies should be
done to provide appropriate data to resolve the question [5].
Meanwhile the US Food and Drug Administration (FDA)
had approved an analgesic combination containing para-
cetamol, aspirin, and caffeine as safe and effective for the
use in uncomplicated migraine [6].
The Scientific Advisory Committee recommended the
new study to be conducted within a relatively short time
period to meet regulatory needs. The Drug Authorities
(Germany, Austria, Switzerland) agreed that the year 2006
is as an acceptable deadline for obtaining final results. The
discussions emphasized that the study should be designed
and conducted in a way that ruled out any possibility of
contamination by prior phenacetin use. In addition, it
was agreed to conduct the study in those countries that
had expressed concern about the problem, since the rele-
vant compound analgesics are available on the markets of
these countries and have a sufficient market share.
A further question to be addressed was whether caffeine
co-formulated with analgesics could lead to a dependence
on analgesics, contribute to heavy long-term use, and
thereby result in a higher risk of ESRD. Although an addi-
tional Expert Meeting on Caffeine found no evidence for
such an effect [7], and although a further special review
did not reveal any substantial data to support a pivotal
role of caffeine [8], the new study was intended to provide
information on the role of caffeine in risk development.
Since ESRD is a rare outcome, a case-control study seemed
to be the appropriate design (initially called "Study on
Analgesic Nephropathy", SAN). Neither a study outside
Europe (where combined analgesics are used to a lesser
extent) nor long-term prospective cohort studies were
regarded as acceptable alternatives, since the latter would
not provide timely results. It was not possible to conduct
a historical cohort study, because the required data were
not available.
The protocol of the case control study as agreed upon by
the Scientific Advisory Committee was approved by the
regulatory authorities of Germany, Austria and Switzer-
land and was also reviewed by 'The Lancet' without any
recommendation for change [personal communication;
Prof. Fox, 2004] The initial study protocol can be read in
the website http://www.san-project.com).
The objective of this publication is to present the study
protocol with some minor revisions as approved by the
Scientific Advisory Committee prior to the final analyses
and subsequent publication in 2006.
Methods/design
General study design and rationale
A case-control study design was chosen because the study
addresses the potential association between a rare medical
condition (ESRD) and a relatively common exposure
(analgesics) and because it needed to be conducted within
a short period of time at affordable costs. Cases would be
individuals initiating dialysis (incident ESRD) at one of
the participating centers, and controls would be taken
from the general population.
Two major concerns influenced the planning of the study:
- To exclude the possibility of inadvertent contamination
with phenacetin among study subjects, study participa-
tion was restricted to individuals under 50 years of age.
While this measure greatly impedes case accrual (only
25% of incident ESRD is within this age range), it assures
minimal phenacetin contamination, because phenacetin
use declined in the 1970ies and the drug was removed
from the market in the countries under study in mid to
late 1980. This age limit assures good recall of drug histo-
ries among these young study subjects and captures the
group most likely to be affected if the metabolite of phen-
acetin, paracetamol, were associated with ESRD.
- The second issue concerns the time from onset of the dis-
ease until the diagnosis of ESRD which leads to dialysis,BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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which is estimated to be between 5 to 10 years. Because
the applicability of this pattern in association with a puta-
tive cause such as analgesic use is unclear, the protocol
permits analyses of lag time and of appropriate
subgroups.
Objectives of the study
The study was designed to address as many questions as
possible about the association between ESRD and analge-
sic use in the range of recommended dosage with suffi-
cient statistical power and in a timely manner.
The primary study objective is to determine whether a sig-
nificant association between the occurrence of ESRD and
the use of phenacetin-free analgesics in the average popu-
lation exists or not.
A. The following three groups are of primary interest in
the context of the main research objectives (basis for sam-
ple size estimations):
- Use of any phenacetin-free analgesics
- Use of any phenacetin-free analgesics in fixed combina-
tions ("combis")
- Use of any phenacetin-free single substance – analgesics
("monos")
B. Drug-specific analyses will be done for groups with suf-
ficient numbers, focusing on paracetamol with and with-
out other analgesics, and with and without caffeine in the
formulation.
C. In addition to the comparison between use and non-
use (see "exposure"), the magnitude of use, such as dose,
duration, cumulative lifetime dose per duration of use
and other measures for the extent of exposure will be
assessed. The desirable sub-group analyses (cf. exposure
groups) are listed in advance for transparency, although it
is recognized that some analyses will lack statistical
power.
If a significant association of analgesic use and risk of
ESRD becomes apparent, the secondary objective of the
study is to analyze the patterns of use among individuals
with excessive analgesics use (over 30% in excess of the
recommended dose) and to address the role of caffeine
co-formulated with analgesics and in conjunction with
caffeine use in beverages, medical conditions, and indica-
tors of general health behavior. This, however, is not part
of the main research question focused on the risk of ESRD
in the average population, i.e. not in specific sub-groups.
Study design
The study is conducted as a multicenter case-control study
in Germany and Austria. New (incident) cases of ESRD
will be collected from dialysis centers. On average, four
population controls will be individually matched per case
for age, gender and region the case came from.
Cases are defined as persons with end-stage renal disease
(ESRD), newly admitted to a chronic dialysis program.
Since there may be a considerable lag time between the
underlying condition and the diagnosis of ESRD and
because the underlying renal disease itself may have led to
the use of analgesics, four index dates preceding the actual
diagnosis of ESRD were defined. All potentially associated
exposures (analgesic use, exposure to other chemicals at
the work site), and conditions or complaints occurring
after a given index date will not be considered in the sta-
tistical analyses. The four index dates were defined as
follows:
• Index date 1: Time of first entry into the dialysis program
for cases; time of personal interview for controls.
• Index date 2: Time the case was first informed about
incipient renal failure from the treating physician; the
index date for the control is the index date of the respec-
tive case.
• Index date 3 represents an arbitrarily defined lag-time of
5 years prior to the start of dialysis; the index date for the
control is the index date of the respective case.
• Index date 4 represents an arbitrarily defined lag-time of
10 years prior to the start of dialysis; the index date for the
control is the index date of the respective case.
Since index date 2 might be subject to information- and
recall bias, index date 3 is considered to be the most reli-
able index date for risk estimates. Index 2 might be used if
the number of analgesic users is too small at index date 3.
The analgesic exposure of cases and controls at index date
4 (10 years before terminal renal insufficiency) was pre-
dicted to become too small for stable analyses, although
this date might be biologically sound. The figure shows
the relationship between index dates and putative analge-
sic use. Note that Index date 2 may have a wide range.
Outcome measure
The outcome measure is the relative risk of ESRD associ-
ated with use of analgesics either as single or combined
formulation: heavy use (see later) vs. no use; lifetime
dose, or duration of use.BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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Study participants
Recruitment of centers
The study aimed to collaborate with as many dialysis cent-
ers as possible in Germany and Austria to guarantee a suf-
ficiently high and complete recruitment of incident ESRD
patients in this young age group. A compensation for the
time spent was offered to controls – if requested- and on
demand to cases (up to 20 €) as well as to dialysis centers
(up to 40€ for completing the medical history and diag-
nostic documentation).
The Clinical Principal Investigators, Prof. van der Woude
for Germany and Prof. Graf for Austria, were responsible
for organizing the recruitment of dialysis centers via the
relevant professional organizations. In Germany, a joint
effort of three nephrological associations under the aus-
pices of the German Kidney Foundation facilitated con-
tacts to hundreds of dialysis centers and thereby a good
study performance. The German Kidney Foundation inde-
pendently approved the study protocol, established an
organizational network for the smooth collaboration
among centers and with the Data Management and Coor-
dination Center (DMCC – ZEG Berlin), and officially
invites the dialysis units on behalf of the German Kidney
Foundation. In Austria, Prof. Graf organized the study
after approval from the Nephrological Association of Aus-
tria, which officially invited the dialysis centers' participa-
tion. In both countries, an information and training
program was introduced for all dialysis centers participat-
ing in the study.
By the end of 2004, 259 dialysis centers had agreed to par-
ticipate in the study and 170 contributed at least one inci-
dent case of ESRD. Details about centers and geographical
distribution can be seen at the website of the SAN study
http://www.san-project.com.
Recruitment of cases and controls
All study participants received a comprehensive letter of
invitation which explained the study objective of investi-
gating various health outcomes with respect to life-time
exposure to chemicals including drug treatment. No refer-
ence to analgesics is made in the invitation letter. The let-
ter in addition provides some sample questions about
exposure to chemicals and health outcomes similar to
those that might be asked in the study interview. One
intention of the letter is to stimulate controls, prior to the
interview, to carefully think about their lifetime history of
exposure to any chemicals, including drugs, in relation to
medical and other conditions. This approach was chosen
to minimize recall bias that could arise because cases in
the past were likely asked more often for potential expo-
sures than controls. Cases may therefore be more fully
aware of previous exposures than controls. The letter was
therefore designed to create a more similar interview situ-
ation for cases and controls by stimulating controls to
reflect about prior exposures and health outcomes before
the study interview.
Cases
Cases are persons with terminal renal failure with a first
admission to renal replacement treatment because of
severe renal insufficiency – end stage renal disease ("ESRD
cases"). Individuals with conditions leading to an acute
dialysis program were not eligible as cases. The renal func-
tion of subjects included as cases was re-evaluated after 3
months. Patients who were found to be acute dialysis
patients or patients for re-dialysis after transplant rejec-
tion were then excluded.
Logbooks were kept in all participating centers for the
duration of their participation in the study to monitor
case accrual and completeness of ESRD patient capture. It
was anticipated that not all centers would be able to par-
ticipate for the entire study period, some entering late,
and others discontinuing for various reasons – e.g. due to
excessive workload.
Cases are eligible if they are new (incident chronic dialy-
sis, not acute or recurrent) and under 50 years of age, if
they are in adequate physical and mental condition to be
interviewed, and if they are willing to participate in the
study as confirmed by signed informed consent. Some of
the new cases reported by the dialysis centers (docu-
mented in the logbook) are expected to meet not the eli-
gibility criteria. It was expected that more than 70% of
reported cases are eligible (eligibility rate). A response rate
of about 80% of all eligible incident cases admitted in the
respective dialysis unit (as documented in their logbook)
was assumed for the sample size calculation.
Cases are invited to participate in the study by the treating
physician at the dialysis center, who explains the objec-
tives of the study as being "research into associations
between chemicals and health". Care is taken that no ref-
erence is made to a suspected association between renal
failure and analgesics. The physician provides the patient
with the invitation letter, which is identical for cases and
controls and which contains details on the interview proc-
ess as well as examples of the questions asked in the inter-
view. If the patient agrees to participate, his or her contact
details are sent to the Data Management and Coordinat-
ing Center (DMCC: ZEG Berlin) that informs the inter-
viewer staff to make an appointment. The interviewer
then visits the patient at home after having made an
appointment. No interview is done without a signed
informed consent form.
All cases and controls were normally interviewed in per-
son at their homes on the basis of a detailed andBMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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structured questionnaire. The same interviewer conducts
all interviews for each case-control cluster (one case and
up to four controls).
The interview provides information about exposure, rele-
vant co-variables, and times of exposure (diary or calendar
method), permitting the full use of the time-related varia-
bles for the statistical evaluation of time dependent data
or pre-planned sub-groups (cf. analyses plan).
Controls
The study is designed to use population controls as refer-
ence group. Eligible controls are persons without ESRD
aged less than 50 years matched individually for age
(same 5-year age group as the case), sex and region of the
respective case at entry in the dialysis program. Controls
are eligible if they are willing to participate in the study,
provide informed consent, and are in adequate physical
and mental condition to be interviewed. Controls may
have any medical conditions except ESRD to be eligible,
because the controls should represent the population
with regard to medical conditions. In equivocal circum-
stances (e.g. controls with kidney stones or other kidney
diseases), controls will be considered separately in the
analysis but will not be stopped to complete the interview.
Controls are recruited after the case interview is com-
pleted and the case's matching region is known. Four
matched controls were tried to accrue per case. If one
potential control refuses participation the next eligible
person replaces him or her. The method of control identi-
fication varies depending on location. Whereas for larger
cities listings of residents form the basis for recruitment,
smaller villages are more suited for random route sam-
pling and neighborhood or telephone contacts.
A response rate of 60% was assumed (after correction for
non-eligible controls resulting from death, incorrect
address, and other reasons that prevent to get into contact
with the potential control person). Based on the experi-
ence from recent population-based case-control studies in
Germany, this response rate is a realistic estimate.
Non-participation, and non-response for cases and 
controls
There are various reasons for non-participation in the
study or exclusion from the analysis for individuals who
were considered initially eligible to participate in the
study.
The dialysis centre for various reasons might inadvertently
miss eligible cases or report cases that are not eligible.
These are documented in the logbook and expressed in
the "eligibility rate" on the basis of all new patients
reported from each of the collaborating centers.
An identified case might become ineligible due to poor
physical or mental condition, insurmountable language
problems, and death after identification but before inter-
view, dialysis outside the study period, or being outside
the age limit. Some of these reasons also apply to ineligi-
bility of population controls. The proportion ineligible
cases for these and other reasons forms the "eligibility
rate" (Number of eligible cases divided by the number of
initially identified cases
Eligible cases or controls may refuse to sign the informed
consent and decline participation, or refuse to complete
the interview. This is called "non-response" in the context
of this study (Number of included/interviewed cases
divided by the number of eligible cases).
Finally, cases or controls will be excluded from the analy-
sis due to the use of any phenacetin-containing analgesic
in any dose during their lifetime.
Exposure and co-variables
Analgesics
The main exposure variable is analgesic use. A lifetime his-
tory of analgesic use is obtained during the personal inter-
view. Memory aids include a list of brand names of
analgesics and an atlas with pictures of packages of all
analgesics, both past and present. Participants are asked
for the brand names, number of daily doses, start and stop
of use, and the reasons/indications for use. The brand
names were used to identify all analgesics whether pre-
scription or over-the-counter (OTC), single-substance and
combination analgesics with and without caffeine, phen-
acetin, or additional substances such as codeine and bar-
biturates. Information is also collected on switching
analgesics and the reasons for switching, as well as on sub-
jective symptoms of "dependence" and psychological or
behavioral patterns.
The exposure definitions are similar to those of two recent
studies in Germany (MURC study [9] and Pommer et al
[10]), to facilitate comparisons with these studies that are
the only available on analgesic use in Germany or Austria,
particularly on OTC analgesics.
The cumulative lifetime use of all analgesics and of spe-
cific analgesic subgroups will be based on grams of the
respective analgesic group (see below). The cumulative
lifetime dose of analgesics will be stratified into tertiles to
obtain the distribution in population controls, being
called low, moderate, and heavy use. The Scientific Advi-
sory Committee (SAC, see later) recommended the use of
the top tertile of lifetime analgesic dose (grams) as the
measure for heavy analgesic exposure in preference to the
definition of "substantial use" as it was defined in the
study protocol before revision. This decision was madeBMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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after data from the population controls in the planned
review (according to the first protocol) showed that the
utilization of analgesics had changed considerably in the
decade since "substantial use" [10] was defined:
- "Heavy users" are defined as persons whose use of anal-
gesics is in the top tertile of the accumulated lifetime dose
in grams. Alternatively, heavy use can also be defined in a
similar way for shorter periods, i.e. not for lifetime but for
any of 12-months periods or other units. In contrast to
lifetime use this was defined as "peak use". However, the
main analyses will be based on cumulated lifetime dose
that will have priority for answering the main research
question.
- "Non-users" are defined as never-users or short-term/
irregular users of any analgesics (<1 dose of analgesic per
month over all possible previous 12-month periods). Par-
ticipants matching this definition are members of a
unique, general reference group which will be identical
across all comparisons.
Persons with recalled use of phenacetin-containing anal-
gesics in the past will be excluded from the main analyses
of the study – even if phenacetin use cannot be confirmed
because of vague recall.
The coding of lifetime use of analgesics follows the discus-
sion and agreement of the Advisory Committee with a
classification into 13 categories (see Table 1).
Due to the low prevalence for some analgesic groups
found in the analyses of the drug use in controls after year
one of the study, two broader categories (sub-categories)
of phenacetin-free analgesics were formed: MONOS (all
monos; paracetamol; ASA; rest of monos) and COMBIS
(all combis; combis with paracetamol; combis without
paracetamol; combis with caffeine; combis without
caffeine).
These categories of lifetime use of analgesics are not mutu-
ally exclusive. Pure groups of users of one type of analge-
sics are very rare and only available for very commonly
used analgesics such as ASA. This distinguishes an obser-
Table 1: Categories of lifetime use of analgesics
Category of analgesics Description
1. Phenacetin-free analgesics All analgesics not containing phenacetin
2. Phenacetin-containing analgesics Analgesics containing phenacetin
3. Mono analgesics (MONOS); phenacetin-free





3.4 Metamizol, Diclofenac, Propyphenazon, Indometacin, 
Aminophenazon, Phenylbutazon)
4. Combination analgesics (COMBIS); phenacetin-free
Combination of more than one active analgesic agent – or – one or 
more analgesic active agent with one or more non-analgesic agents
4.1 Paracetamol + caffeine (Paracetamol and caffeine, no other analgesic 
or non-analgesic agent)
4.2 Paracetamol + ASA (Combination of paracetamol and ASA, no other 
analgesic or non-analgesic agent, no caffeine, no codeine, no barbiturates
4.3 Paracetamol + ASA + Caffeine (Combination of paracetamol and 
ASA and caffeine, no other analgesic or non-analgesic agent)
4.4 Other monos + Caffeine (One other analgesic agent – except 
phenacetin or paracetamol with caffeine, no additional non-analgesic 
agents
4.5 Other combis without caffeine (Two or more analgesic agents – 
except combination paracetamol + ASA with or without non-analgesic 
agents, or one analgesic agent with one or more non-analgesic agents, 
but no caffeine, no codeine, no barbiturates.
4.6 Other combis + caffeine (ASA or paracetamol and/or other analgesic 
agents and caffeine, no phenacetin, no codeine, no barbiturates)
4.7 Combis with codeine and/or barbiturates (One or more analgesic 
agents and codeine and/or barbiturates, independent of other agents, i.e. 
even with additional caffeine, but no phenacetin.BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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vational study from a clinical trial and requires an analysis
adapted to the prevalence in users as found in the data-
base. The magnitude of usage (lifetime dose, peak dose,
duration, dose per duration of use) will be examined by
categorizing these variables into tertiles or other group-
ings depending on the number of users in each group.
Other variables
The following co-variables, evaluated as independent risk
factors for either initiation or promotion of ESRD, will be
considered as potential confounders or effect modifiers of
a potential association between ESRD and analgesic use:
Age, sex, education, region, selected conditions (renal dis-
eases, urinary tract infections, family history of renal dis-
eases, repeated abdominal X-ray, psychological
conditions), co-medication (rheumatic drugs, immuno-
suppressants, anti-cancer drugs, antibiotics, self reported
dependence on any drugs), complaints (gastrointestinal,
heart, vomiting, depression, anxiety, sleeplessness,
fatigue, irritability, stress, eating problems, and various
pain [joints, back pain, migraine, other headache, men-
struation), and exposure to potentially nephrotoxic agents
at the work site (such as heavy or other metals, special or
general silicates, solvents, soldering/welding fumes).
Sample size estimation
The sample size needed to address the three main research
questions was estimated with the following assumptions:
Alpha 5%, beta 20% (power 80%), case-control ratio 1:4,
minimal detectable risk (odds ratio) 2.0, and revised prev-
alence of heavy analgesic use (lifetime dose in grams; top
tertile of use in each of the analgesic groups; adapted to
the more accurate estimates from the study population;
old estimates (see http://www.san-project.com) based on
empirical data of population controls of the SAN study
from end 2003 (see table 2). The sample size of cases and
controls in table 2 is based on prevalence estimates of
heavy use in different analgesic groups and thereby pro-
vides an impression what comparisons are likely or
unlikely to be finally analyzed.
We conclude from this table that our initial estimate of
the required sample size (cf. 1st study protocol in http://
www.san-project.com) is still roughly valid. About 1000
cases of ESRD need to be identified in the co-operating
dialysis centers to include 800 cases and 3200 controls in
the final analysis which would result in sufficient power
for the analysis of the main study questions and would
additionally provide results for many but not all of the
subgroups.
Quality control & assurance measures
Quality control and assurance measures are implemented
to ensure that the procedures and data are reasonably
valid, and compatible within and among centers and
between cases and controls.
The quality assurance measures were directed at the inter-
view technique, the preparation of the field work, the con-
duct of the study, and finally at the plausibility of the
database. The interview was standardized and the ques-
tionnaire was tested in a pilot phase for the clarity of its
items. The interviewers were trained and re-trained and
Table 2: Number of cases and controls needed to detect a 2-fold risk (alpha 5%, 1-beta = 80%). Comparison of heavy analgesic use (top 
tertile in grams) vs. non use in the respective categories of analgesics. Important: the subcategories are not mutually exclusive and 
cannot be added up to 100%.
Prevalence in controls (%) Nb of cases Nb of controls
All analgesics (phenacetin-free) 22.8 104 416
Phenacetin-containing 2.5 616 2464
MONOS
Paracetamol 5.3 308 1232
ASA 15.7 129 516
Ibuprofen 2.1 728 2912
Other monos 5.0 324 1296
COMBIS
Paracetamol+caffeine 0.1 14 670 58 680
Paracetamol+ASA 0.9 1657 6628
Paracet+ASA+caffeine 4.1 388 1552
Others+caffeine 0.6 2470 9880
Other combis without caffeine 3.5 449 1800
Other combis+caffeine 3.3 475 1900
Combis with codeine or 
barbiturates
1.9 654 2616BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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appropriate explanations were integrated into the inter-
viewer training plan and guideline. A set of aids was intro-
duced to reinforce the memory of study participants such
as picture displays of analgesic packages, tables with lists
of drugs for the study subject to read etc. to avoid recall
bias. Training and retraining of all personnel involved in
the study was done: of investigators, abstractors of medi-
cal records, interviewers, following a standardized train-
ing plan.
A detailed logbook was kept in each of the participating
dialysis centers. This provides information on the eligibil-
ity or ineligibility of cases and controls, participation rates
and the reasons for non-responses or non-participation,
the status of recruitment and other details. Additionally,
site visits were done, if required.
Incoming data were checked in the Data Management and
Coordinating Centre Berlin for quality and comprehen-
siveness by a sophisticated quality assurance system and
queries were made to the study center if there was doubt
about the validity of the data or if there were missing data.
Data management and analysis plan
Data management
The data were collected locally and thereafter transferred
to the central Data Management and Coordination Centre
(DMCC) Berlin according to clear time lines and defined
responsibilities. The DMCC consists of ZEG Berlin (data
management) and EPES Berlin (data analysis).
The data were entered into the database and thoroughly
checked for errors and plausibility. The database will then
be transferred into the "clean data set" that will contain
the following groups of data:
1. Case/control variable ESRD (diagnostic categories, time
variables as far as available)
2. Main exposure variables – use of analgesics (up to the
time of respective index dates)
3. Co-variables:
- Co-morbidity: renal, circulatory, metabolic, psychiatric,
and other conditions; headache and other painful
conditions;
- Treatment history: types of treatment with potential rela-
tion to outcome and risk factors;
- Exposure to caffeine: coffee, tea, and caffeine-containing
beverages;
- Job exposure: occupation & industrial branch; exposure
in selected occupational categories; exposure to groups of
certain chemicals/minerals;
- Other personal data: Age, sex, centre, health care con-
tacts, socio-demographic markers
4. Factors potentially related to overuse of analgesics: psy-
chological / vegetative / psychiatric conditions; behavioral
factors (such as smoking, alcohol, physical activity).
Several databases will have to be established for different
analyses which relate to the different index dates, different
classifications of user groups of analgesics etc.
Analysis plan
In the final analysis, appropriate multivariate analyses
will be done to assure that the risk estimates for ESRD and
use of phenacetin-free analgesics are appropriately
adjusted for confounding and effect modification. A
detailed analysis plan was discussed at the meeting of the
SAC in April 2004, and approved after revisions. Briefly,
the "core analyses" will include:
- Information on selection such as included cases by
regions/country, non-participation rate by case/control
status, non-response rate by case/control status, reasons
for non-participation and non-response by case/control
status.
- Frequency distributions of exposure with analgesics by
case/control status and by index dates such as ever vs.
never use, lifetime dose (grams) in tertiles vs. non-use,
duration of use (years) in tertiles vs. non-use, density of
use (dose per duration of use).
- Logistic regression analyses of ESRD and analgesic expo-
sure by index dates: Ever vs. never use, lifetime dose
(grams) in tertiles vs. non-use, duration of use (years) in
tertiles vs. non-use, density of use (dose / duration).
Several methodological issues will be addressed in the
analyses:
One such issue relates to the precise definition and status
of the index dates. Index date 1 is used only for descrip-
tion of the group of cases and controls, but not for the
interpretation of the risk of nephropathy. The preferable
index time for risk estimates is index 3. If the exposure
data at index date 3 are insufficient, then SAC endorsed
the use of index date 2.
The analgesic groups analyzed in the "core analyses" are
not mutually exclusive. This means that the analysis of
heavy lifetime use in one specific analgesic group is usu-BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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ally contaminated by use in other analgesic subgroups. It
is unlikely to find sufficiently large "mutually exclusive
groups of heavy analgesic use" will exist in the database.
Moreover, it is unlikely that a satisfactory statistical
approach for this problem will be found. The final deci-
sion on which method will be employed depends on the
quantity of data available.
The inclusion of dosage of a specific analgesic subgroup
(grams) as a continuous variable was discussed to provide
a more comprehensive analysis of the dose-response
effects in the "normal" user population. Such a variable
might preferably be defined in broader categories of
grams, showing not the increase of risk per one gram but
per 10 or 50 or 100 or even 500 grams of lifetime dose.
An analysis of peak use might be appropriate if the data
indicate a consistently increased risk in some of the anal-
gesic subgroups. Peak use is defined as high use within a
brief period of time (12 month) with only little or average
use before and after this episode. This approach differs
from the analyses of the cumulated lifetime dose, and it is
not the focus to answer the main research question.
These and other data-driven analyses are suitable to test or
confirm the biological plausibility of results. However,
these analyses are hypothesis generating and will not be
conducted to answer the planned main research
questions.
The final analysis will face the problem of small numbers
in many analgesic subgroups. The SAC strongly recom-
mended reducing the number of adjustment variables to
an absolute minimum. The appropriate statistical meth-
ods will be applied to select the most important con-
founders to get more stable risk estimates for small
numbers. Further, the committee recommended not cal-
culating or report adjusted odds ratios if any cell contains
less than 10 subjects.
The findings must be interpreted with the consideration
in mind that numerous analyses will be done to scrutinize
the many available databases. Therefore it is statistically
expected that some significant results will be found. This
does not necessarily reflect a causal association because it
may be a statistical artifact. The option of controlling for
multiple testing in an observational study was discussed
but not finally decided. It might be sufficient to interpret
the results with great caution without formally applying
further statistical procedures.
Study management
The management of the study with regard to clinical/
nephrological aspects, including recruitment of co-operat-
ing dialysis centers, is the responsibility of Prof. van der
Woude (V. Medizinische Klinik- Nephrologie, Klinikum
Mannheim, Medizinische Fakultät der Universität Heidel-
berg) for Germany, and of Prof. Graf (Abteilung für Neph-
rologie des Krankenhauses Rudolfstiftung in Wien) for
Austria.
The management of the whole study with regard to epide-
miological expertise, data management and analyses is
the responsibility of Prof. Heinemann (Centre for Epide-
miology & Health Research Berlin).
The three Principal Investigators mentioned above form
the Managing Committee of the SAN study in Germany
and Austria.
The German Kidney Foundation plays a key role in sup-
porting the study, particularly with regard to co-operation
with the three German Nephrological Associations (see
acknowledgments) and thereby with the collaborating
dialysis centers. The same role plays the Austrian Nephro-
logical Association for this country.
Agreements on terms of reference of various partners in
the study, on ownership of data, accessibility of the data-
base, and publication policy are available on the website
of the SAN study http://www.san-project.com. This web-
site also contains the current status of the fieldwork and
other accessible data.
Advisory committees
The scientific advisory committee (SAC) was jointly nom-
inated by the Drug Authorities and the Industry. It con-
sists of internationally acknowledged experts for different
fields of expertise. The terms of reference of this commit-
tee and the names of its members are detailed in annex 1
and on the SAN website http://www.san-project.com. The
SAC also discussed and approved revisions of the proto-
col. It will finally approve the main analyses and the main
publication prior to submission.
Delegates of the Nephrological Associations (three Ger-
man and one Austrian Association) formed a Steering
Committee to support the study. Two members of each
Association of the two countries where the study is con-
ducted have a seat in this advisory committee. The steer-
ing committee received monthly reports from the study. It
can request additional information, and supports the
study by identifying and resolving problems that occur
within the study period. Details about Terms of Reference
and names of members can be found on the SAN website
http://www.san-project.com.
Communication
Periodic reports of study progress are made to the SAC,
and the Steering Committee of the study.BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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Additionally, annual interim analyses for selected ques-
tions were submitted to the SAC for discussion and to get
advice. Summaries of the annual reports were submitted
to interest Drug Regulators only after approval by the SAC.
A publication policy was agreed with the collaborating
study centers (see http://www.san-project.com for
details).
The study will be analyzed and published in 2005/06.
Discussion
Because confounding and bias can affect every observa-
tional study, potential forms of bias received special con-
sideration in the design of the initial study protocol in
2000/2001. Several sources of bias, such as recall bias,
selection bias, reverse causality (protopathic) bias, inter-
viewer bias, and (residual) confounding have been
addressed in critical reviews of previous case-control stud-
ies on the association between analgesics and kidney dis-
ease [5,6] and were of concern in the design of this case-
control study.
Recall bias assumes a differential recollection of exposures
between cases and controls. In order to minimize recall
bias, cases and controls are interviewed in their homes to
provide for a comparable interview situation. Interviewers
are trained to conduct standardized interviews using the
same material in cases and controls. Visual and other aids
are used to facilitate memory. These include lists of the
trade names of analgesics and other drugs which were or
are on the market, pictures of packages of different analge-
sic brands etcetera. Drug use is ascertained according to
the calendar method so that a lifetime history of analgesic
use can be constructed for each study subject. Interviewers
are trained to ask for beacon points in the patients' lives in
order to facilitate memory of the time period of drug use.
Although differential recall often tends to lead to inflated
risk estimates, it is also of concern in this study that
patients with analgesic nephropathy may deny their pre-
vious analgesic intake that would bias the risk estimate for
analgesics towards the null. Therefore, in the personal
interview, questions about medical conditions for which
analgesics may have been taken precede questions about
analgesic drug use. If the patients report medical condi-
tions for which analgesics may have been used but do not
report exposure to analgesics the interviewers have been
instructed to ask the patients again about drug use for the
respective conditions.
Selection bias: Since it was assumed that cases of ESRD are
equally identified among analgesic users and nonusers
due to the severity of their medical condition, exposed
subjects should not have a higher likelihood of being
selected into the study. This could be a problem if cases
were defined as patients with early renal disease and anal-
gesic users had more serum creatinine measurements
done and therefore a higher likelihood of being detected
as a case. For the endpoint ESRD no selection bias due to
differential selection of exposed cases is anticipated.
Selecting cases with advanced disease has been criticized
in previous case-control studies, since the etiologically rel-
evant exposures are those that antedate the onset of dis-
ease and not those that antedate end-stage renal disease.
To address this concern, several index dates are considered
(see reverse causality bias).
The study uses a largely population-based approach (pri-
mary study base) by attempting to recruit all regional dial-
ysis units located in these regions (usually federal states),
enrolling all incident cases in these units into the study
and by selecting population controls from the same
regions where the case came from. The representativeness
of the control group can be investigated by comparing
characteristics in controls to those in the population using
official statistics as a source.
A system of motivation and reminder is in place to assure
adequate response rates in both cases and controls. In
order to avoid non-participation of cases with analgesic
nephropathy, the information on the type of question in
the study information is subtle and avoids mentioning of
analgesics.
Reverse causality (protopathic) bias is also of concern in
this study. Chronic renal disease may lead to symptoms or
physical changes (for example backache, headache,
malaise, intercurrent infections, fever etc), which in turn
may lead the patient to use analgesics. Exposure to analge-
sics in cases of ESRD may therefore reflect exposure which
truly started before the chronic renal disease process or
which was a consequence of the disease process.
It is very difficult to address this type of bias in a case-con-
trol study. To minimize reverse causality bias, several
index dates are considered in the statistical analyses. One
index date to be considered is the date the renal disease
was first suspected/diagnosed (taken from the interview
where the patient is asked when the doctor first men-
tioned an increased serum creatinine level). However, this
date may already represent an advanced stage of the dis-
ease, since chronic renal disease commonly has an insidi-
ous onset and therefore is often not diagnosed in the early
stages. Therefore, two other index dates are considered
which are based on fixed lag-times of 5 and 10 years. This
approach is commonly used in cancer epidemiology and
avoids bias by (differential) detection of the disease. Dis-
crepancies in results between index date 5 and 10 years
could be indicative of protopathic bias (cf. discussion).BMC Nephrology 2005, 6:9 http://www.biomedcentral.com/1471-2369/6/9
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Protopathic bias cannot be ruled out if the risk estimate
for ESRD in analgesic users is increased with use of the
index date with a lag time of 5 but not with a lag time of
10 years., According to recommendations of the SAC, the
index date with a lag time of 5 or 10 years is given priority
in the analysis to avoid protopathic bias (see above).
Interviewer bias: Although it will not be possible to blind
interviewers to the case or control status, interviewers are
blinded to the main study hypothesis. The interview does
not only ask about kidney disease, but also about a broad
range of health outcomes. Furthermore, interviewers
acquire information not only about the use of analgesics,
but also about exposure to many other drugs as well as
exposure to many chemicals at the work place.
Confounding:  Previous studies were criticized for con-
founding by chronic phenacetin use. In this study, chronic
phenacetin use will be identified by means of a database
that lists the names of all analgesics that contained phen-
acetin in the past and the respective time periods in which
these analgesics contained phenacetin (since the compo-
sition of analgesics was often changing in Germany, but
the trade name of the drug remained the same). With this
database and the calendar method in the interview it will
be possible to identify patients with significant phenace-
tin use and exclude them from testing the main study
hypotheses. This study should provide a better opportu-
nity to study the association between phenacetin-free
analgesics and chronic renal disease than previous case-
control studies, since only patients below age 50 are
included. Also, many of the earlier studies were conducted
more than 10 years ago when phenacetin use had not
been banned long enough to enroll a large enough
number of patients without significant phenacetin use.
Now, more than 10 years later, this will be more likely
possible.
Due to methodological limitations of previous case-con-
trol and cohort studies the definition of significant phen-
acetin use is not straightforward. The cumulative amount
of phenacetin that carries an increased risk of chronic kid-
ney disease (and therefore which patients with phenacetin
use in the past are to be excluded) is not clear. If the
threshold value for significant phenacetin use defined is
too high, residual confounding by phenacetin use may
lead to an inflated risk estimate for non-phenacetin con-
taining analgesics. Previous studies have shown high risk
estimates for ≥ 1 kg cumulative dose of phenacetin:
McCredie (1988)[11]: OR = 19 (10–37); Pommer
(1989)[10]: OR = 9 (2–39) and also for regular use of
phenacetin: Morlans (1990)[12]: OR = 19 (2–157); San-
dler (1989)[13]: OR = 5 (1.7–14.9). Some studies have
also suggested an increased risk for smaller doses of phen-
acetin. McCredie observed an odds ratio of 15 (8–28) for
≥ 0.1 kg of phenacetin (compared with < 0.1 kg of phen-
acetin) and in the study by Pommer [10], a significant
increase in risk was observed for cumulative doses of
phenacetin of 100–499 g of phenacetin (OR = 1.99 (1.14–
3.48)) and 500–999 g (OR = 2.58 (1.19–5.59). No
increased risk was observed in this study for cumulative
doses of phenacetin of less than 100 g. Sandler[13] also
observed an increased odds ratio for lower doses of phen-
acetin (OR = 1.92 (1.06–3.49) for weekly use of phenace-
tin defined as use at least once a week for at least one
year). To avoid confounding by residual phenacetin use,
we will exclude all cases and controls with any detectable
phenacetin use from the test of the main study
hypotheses.
It is also very important to ascertain information on med-
ical conditions which can independently affect kidney
function and lead to an increased use of analgesics such as
rheumatic disorders, diabetes, hypertension, kidney
stones etc. This study carefully collects information on
these conditions and their date of occurrence in the med-
ical documentation form and in the interview in order to
be able to control for these conditions in the statistical
analyses.
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The Scientific Advisory Committee (SAC)
Prof. A. R. Feinstein, Dept. Epidemiology, Yale University,
Medical School, New Haven, USA: (Chairman until end
2001, died)
Prof. K.-M. Koch, Abt. Nephrologie, Medizinische Hochs-
chule Hannover, Hannover, Deutschland: (Chairman
from 2002)
Prof. S. Shapiro, Div. Epidemiology, School of Public
Health, Columbia University, New York, USA (from
2002)
Prof. P. Bauer, Institute for Medical Statistics, University of
Vienna, Vienna, Austria
Prof. E. Delzell, Occupational Epidemiology, Scholl of
Medicine, University Birmingham, USA
Dr. G. Curhan, Channing Laboratory, Harvard University,
Boston, USA (until 2004)
Prof. J.M. Fox, University of Saarland, Germany
Prof. P. Michielsen, University of Leuven, Belgium
Prof. S. Suissa, Pharmacoepidemiology Research Unit,
Div. Clinical Epidemiology, McGill University, Montreal,
Canada
Dr. B. Kasiske, Internal Medicine & Nephrology, Henne-
pin County Medical Center, University Minneapolis, Min-
neapolis, USA (from 2002)
Prof. M. Mihatsch, Institute for Pathology, University
Basel, Switzerland
The Steering Committee (SC)
Prof. Dr. H. Holzer, Nephrologie, Universitätsklinik,
Graz, Austria
Prof. Dr. W. H. Hörl, Medizinische Klinik III am Allge-
meinen Krankenhaus der Stadt Wien, Austria
Prim. Doz. Dr. H.K. Stummvoll, Krankenhaus der Elisa-
bethinen, Linz, Austria
Prof. Dr. Florian Lang, Generalsekretär der Gesellschaft
für Nephrologie, Tübingen, Germany
Index dates and relationship with putative analgesic use in the SAN case-control study Figure 1
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Prof. Dr. D. Schlöndorff, Medizinische Poliklinik Klini-
kum Innenstadt, München, Germany
Prof. Dr. T. Risler, Leiter der Sektion Nephrologie,
Medizinische Klinik III, Tübingen, Germany
Prof. Dr. W. Boesken, II. Medizinische Abt., Krankenhaus
der Barmherzigen Brüder, Trier, Germany
Prof. Dr. G. Schultze, Dialyse Institut Villingen-Schwen-
ningen, Germany
Study coordination
Germany: Dr. A. Busauschina, Dr. P. Schnülle (Klinikum
Heidelberg-Mannheim, 5. Med. Klinik – Nephrologie,
Mannheim, Germany
Austria: K. Stadler (2001/2002), G. Schneidewind (from
2002)
International coordinating and data management center
Organization of field work, quality management, and
data management: A. Assmann, Dr. S. Möhner, Dr. T.
DoMinh (ZEG Berlin),
Data analyses: D. Kuehl-Habich (EPES Berlin)
Advisor for Clinical Pharmacology of analgesics: Dr. K.
Farker, Institute for Clinical Pharmacology, Jena,
Germany
Statistical advisory group
Prof. Dr. S. Suissa, McGill University Montreal, Canada
Prof. Dr. P. Bauer, University of Vienna, Austria
Prof. Dr. J. Röhmel, German Drug Authority, Bundesinsti-
tut für Arzneimittel und Medizinprodukte, BfArM, Bonn,
Germany
Collaborators in dialysis centers
The collaborators in the 170 German and Austrian dialy-
sis centers are listed in the study website http://www.san-
project.com.
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